Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PureTech Health plc (PTCHF)
Boston, MA, US
PureTech Health plc operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts in the United States on the discovery, advancement, and market introduction of novel therapeutic solutions. The company's diverse pipeline targets a wide array of challenging medical conditions, including inflammatory, fibrotic, and immunological disorders, intractable cancers, various lymphatic and gastrointestinal issues, as well as neurological and neuropsychological ailments. Among its significant offerings, PureTech provides KarXT, a treatment designed to modulate muscarinic acetylcholine receptors for managing schizophrenia and the psychosis seen in Alzheimer's disease. Its technological foundations also encompass a regenerative biology platform applicable to conditions like androgenetic alopecia and epithelial aging, alongside an immunomodulation platform dedicated to addressing chronic and acute inflammatory disorders. Additionally, the firm develops oral therapies derived from specific bacterial consortia isolated from the human microbiome and treatments engineered to alleviate cognitive dysfunction associated with depression, multiple sclerosis, post-COVID and ICU recovery, and cancer-related conditions. Further innovations include hematopoietic stem cell-based therapies for individuals with blood cancer, a voice-activated technology platform capable of identifying health-related vocal shifts, and a proprietary system facilitating the oral delivery of biologics, vaccines, and other complex medications. In its robust development pipeline, PureTech is advancing LYT-100 for the treatment of lymphedema and other lymphatic flow anomalies, LYT-200 as an IgG4 monoclonal antibody targeting galectin-9, and LYT-210 for solid tumors. Pioneering technological frameworks under development include Glyph, a synthetic chemistry platform for lymphatic targeting; Orasome technology, which enables oral administration of large molecule therapeutic payloads; a meningeal lymphatics platform with implications for Alzheimer's and Parkinson's diseases; and the Alivio technology platform, designed for inflammation-targeted disease immunomodulation. PureTech Health plc has forged key collaboration and licensing agreements with leading pharmaceutical companies, including Boehringer Ingelheim International GMBH, Eli Lilly and Company, Imbrium Therapeutics L.P., and Shionogi & Co., Ltd. The company was founded in 2015 and maintains its corporate headquarters in Boston, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +8.33% | -0.59% | +0.60% | -1.17% | +2.42% | -33.73% | -67.99% | -6.63% | -29.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+10.4% ★ Q4'25: +1,444.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-335.0% Q4'25: -86.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-3,074.5% Q4'25: -1,342.3% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-2,114.8% Q4'25: -1,868.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-216.1% Q4'25: -441.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-10.7% ★ Q4'25: -12.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.20× Q4'25: -0.10× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.74M
est: 15.27M (-23.1%)
|
4.43M
est: 2.66M (+66.3%)
|
650.0K
est: 1.58M (-58.9%)
|
16.37M
est: 26.55M (-38.3%)
|
8.69M
est: 25.71M (-66.2%)
|
8.34M
est: 15.71M (-46.9%)
|
9.98M
est: 15.30M (-34.8%)
|
2.09M
est: 15.95M (-86.9%)
|
750.0K
est: 9.20M (-91.8%)
|
4.32M
est: 30.50M (-85.9%)
|
4.76M
est: 3.70M (+28.7%)
|
49.50M
49.50M – 49.50M
+1,237.8% YoY
|
228.20M
228.20M – 228.20M
+361.0% YoY
|
473.80M
473.80M – 473.80M
+107.6% YoY
|
| EBITDA |
-49.42M
est: 3.05M (-1,718.8%)
|
-77.39M
est: 532.8K (-14,625.2%)
|
-42.85M
est: 316.5K (-13,637.5%)
|
-37.60M
est: 5.31M (-808.1%)
|
476.06M
est: 5.14M (+9,158.7%)
|
-144.76M
est: 3.14M (-4,705.8%)
|
26.25M
est: 3.06M (+757.7%)
|
-51.24M
est: 3.19M (-1,706.3%)
|
-11.91M
est: 1.84M (-747.1%)
|
37.38M
est: -6.10M (+712.8%)
|
-97.29M
est: -740.0K (-13,048.0%)
|
-9.90M
-9.90M – -9.90M
-1,237.8% YoY
|
-45.64M
-45.64M – -45.64M
-361.0% YoY
|
-94.76M
-94.76M – -94.76M
-107.6% YoY
|
| EBIT |
-50.14M
est: 3.05M (-1,742.2%)
|
-82.74M
est: 532.8K (-15,629.9%)
|
-70.01M
est: 316.5K (-22,218.5%)
|
-68.05M
est: 5.31M (-1,381.5%)
|
481.12M
est: 5.14M (+9,257.0%)
|
21.92M
est: 3.14M (+597.3%)
|
-54.24M
est: 3.06M (-1,872.5%)
|
-59.97M
est: 3.19M (-1,980.0%)
|
-16.96M
est: 1.84M (-1,021.7%)
|
33.81M
est: -6.10M (+654.3%)
|
-100.72M
est: -740.0K (-13,510.5%)
|
-9.90M
-9.90M – -9.90M
-1,237.8% YoY
|
-45.64M
-45.64M – -45.64M
-361.0% YoY
|
-94.76M
-94.76M – -94.76M
-107.6% YoY
|
| Net Income |
-39.39M
est: -38.66M (-1.9%)
|
-48.79M
est: -80.09M (+39.1%)
|
26.47M
est: -89.15M (+129.7%)
|
-43.65M
est: -53.15M (+17.9%)
|
421.14M
est: -116.67M (+461.0%)
|
5.99M
est: 62.29M (-90.4%)
|
-60.56M
est: -137.12M (+55.8%)
|
-50.35M
est: -107.51M (+53.2%)
|
-65.70M
est: -169.04M (+61.1%)
|
53.51M
est: -163.74M (+132.7%)
|
-112.18M
est: -145.44M (+22.9%)
|
-155.79M
-155.79M – -155.79M
-7.1% YoY
|
-166.87M
-166.87M – -166.87M
-7.1% YoY
|
98.24M
98.24M – 98.24M
+158.9% YoY
|
| SGA |
18.38M
est: 132.94M (-86.2%)
|
37.16M
est: 23.20M (+60.2%)
|
46.28M
est: 13.78M (+235.8%)
|
24.43M
est: 231.20M (-89.4%)
|
34.89M
est: 223.89M (-84.4%)
|
26.50M
est: 136.85M (-80.6%)
|
30.76M
est: 133.24M (-76.9%)
|
35.67M
est: 138.90M (-74.3%)
|
49.53M
est: 80.12M (-38.2%)
|
27.49M
est: 591.05M (-95.3%)
|
20.65M
est: 71.70M (-71.2%)
|
959.24M
959.24M – 959.24M
+1,237.8% YoY
|
4.42B
4.42B – 4.42B
+361.0% YoY
|
9.18B
9.18B – 9.18B
+107.6% YoY
|
| EPS |
-0.21
est: -0.14 (-46.5%)
|
-0.21
est: -0.30 (+29.3%)
|
0.13
est: -0.33 (+139.3%)
|
-0.16
est: -0.20 (+18.8%)
|
1.54
est: -0.43 (+455.9%)
|
0.02
est: 0.23 (-90.3%)
|
-0.21
est: -0.51 (+58.7%)
|
-0.18
est: -0.40 (+54.9%)
|
-0.24
est: -0.63 (+61.7%)
|
0.20
est: -0.68 (+129.4%)
|
-0.47
est: -0.60 (+22.2%)
|
-0.65
-0.65 – -0.65
-7.1% YoY
|
-0.69
-0.69 – -0.69
-7.1% YoY
|
0.41
0.41 – 0.41
+158.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daphne Zohar | Founder | 618.6K | female |
| Robert S. Langer Jr. | Co-Founder & Non-Executive Director | 270.0K | — |
| Anita Terpstra | Senior Vice President of Intellectual Property | — | female |
| Charles Sherwood | General Counsel & Company Secretary | — | male |
| David R. Elmaleh | Co-Founder & Senior Advisor | — | — |
| Eric Elenko | Co-Founder & President | — | — |
| Lauren A. White | Chief Financial Officer | — | female |
| Michael Inbar | Chief Accounting Officer | — | male |
| Robert Lyne | CEO & Director | — | male |
| Aleksandra Filipovic | Head of Oncology | — | female |
| Spencer Ball | Executive Vice President of Human Resources | — | male |
| Allison Mead Talbot | Senior Vice President of Communications & Head of Investor Relations | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PTCHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
